KEYUF yields 4.07% · JNJ yields 2.14%● Live data
📍 KEYUF pulled ahead of the other in Year 1
Combined, KEYUF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of KEYUF + JNJ for your $10,000?
Keyera Corp. engages in the energy infrastructure business in Canada. The company operates through Gathering and Processing, Liquids Infrastructure, and Marketing segments. The Gathering and Processing segment owns and operates raw gas gathering pipelines and processing plants, which collect and process raw natural gas, remove waste products, and separate the economic components primarily natural gas liquids; and provides condensate handling services. This segment has approximately 4,400 kilometers of gathering pipelines; and holds interests in 12 active gas plants in Alberta. The Liquids Infrastructure segment provides gathering, processing, fractionation, storage, transportation, liquids blending, and terminalling services for natural gas liquids (NGLs) and crude oil through a network of facilities that include underground NGL storage caverns, above ground storage tanks, NGL fractionation and de-ethanization facilities, pipelines, rail and truck terminals, NGL blending facilities, and the Alberta EnviroFuels facility. This segment also produces iso-octane. The Marketing segment engages in the marketing of propane, butane, condensate, and iso-octane, as well as liquids blending activities. The company was formerly known as Keyera Facilities Income Fund and changed its name to Keyera Corp. in January 2011. Keyera Corp. was founded in 2003 and is headquartered in Calgary, Canada.
Full KEYUF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.